Hospital

Well-defined core values can take pharmacy operations to the next level.

Investigators find that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body’s control of blood sugar and BP.

The prior authorization process often involves complex transactions and increases the burden not only on physicians and pharmacies, but can also impact patient access.

Limited empirical data from new study suggests correlations between obesity and individual SDOH, such as education level, food environment, income, and neighborhood.

In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5 to an on-study median of 2.3, which is a 54.7% reduction.

The research team found that levels of depression are at least 3 times higher than before the COVID-19 pandemic.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

Faricimab-svoa targets and inhibits 2 disease pathways that drive diabetic macular edema and neovascular or “wet” age-related macular degeneration.

Although men are more likely than women to be admitted for a hypertensive crisis, women have similar hospital mortality rates.

The men were assessed for neuroticism—or the tendency to interpret situations as stressful, threatening, or overwhelming—and worry levels through 2 mail-in surveys.

The 2-dose Spikevax COVID-19 vaccine was approved by the FDA based on a comprehensive submission package including efficacy and safety data approximately 6 months after the second dose.

The pill molnupiravir and the intravenous drug remdesivir were just as effective against the omicron variant as they were against earlier strains.

The results of a new UCLA-led study show that the pandemic has exacerbated disparities in care, widening inequities.

The study also found conflicting feelings, as participants seemed overwhelmed by too many recommendations while simultaneously perceiving cancer as an unavoidable death sentence.

Anna Legreid Dopp, PharmD, the Senior Director of Clinical Guidelines & Quality Improvement at ASHP, and Bayli Larson, PharmD, the Strategic Initiatives Associate at ASHP, discuss the grant the ASHP received from the American Rescue Plan.

Umbralisib (Ukoniq) is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.

Interventions to improve medication adherence may have a greater impact on individual patients and the population as a whole than any novel treatment or therapy.

The study will have 3 cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an omicron-based vaccine and will use participants from the phase 3 COVID-19 booster study.

The findings suggest that pregnant women should not delay COVID-19 vaccination until late pregnancy.

The analysis of 204 countries and territories reveals that AMR is now a leading cause of death worldwide, which is higher than HIV/AIDS or malaria.

Women had lower health-related quality of life at the beginning of the study, although men experienced a more rapid decline over time.

Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discusses some trends and predictions for health care IT this year and on into the future.

Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.

Mitchel Rothholz, RPh, MBA, chief of governance and state affiliates at the American Pharmacists Association (APhA) and executive director of the APhA Foundation, discusses the results of a nationwide survey of pharmacists during the ongoing pandemic.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.

The tislelizumab combination met the primary endpoint of OS in patients with programmed death ligand 1 (PD-L1) expression, with additional follow-up needed to assess OS benefits in the intention-to-treat population.